Treatment

JNJ-42756493, JNJ-42756493, JNJ-42756493 clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations
This study is testing a new medicine, JNJ-42756493, for adults and children with advanced cancers that have a specific genetic change called an FGFR alteration. Researchers want to see if the medicine can shrink or make these cancers disappear.
For: Advanced solid tumors (other than Urothelial tumors), and FGFR gene · alterations.
Germany · Spain